GlassScriptPhysician profile
Kevin Dunn
NPI 1558006809
$603.14
in general payments reported to CMS, 2019-2025
12 companies · $603 in 2025
The $603 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $139.83 | 2025 | Ozempic, Rybelsus |
| Abbvie INC. | $134.61 | 2025 | |
| Novus Surgical Consultants | $72.93 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.38 | 2025 | Jardiance |
| Astellas Pharma US INC | $37.39 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.16 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $30.13 | 2025 | Trintellix |
| Sumitomo Pharma America, INC. | $24.35 | 2025 | Gemtesa |
| Amgen INC. | $17.88 | 2025 | Prolia, Evenity |
| Tolmar, INC. | $17.72 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $16.70 | 2025 | Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $14.06 | 2025 | Recorlev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.